免疫检查点阻断治疗黑色素瘤脑转移的疾病控制与生存模式
该回顾性研究纳入2005至2017年两个三级中心接受免疫检查点阻断(ICB)单药治疗的385例转移性黑色素瘤患者,其中177例有脑转移。脑转移患者预后较差,且多于1个脑转移者生存更差;颅外病灶疾病控制与生存改善相关,但颅内疾病控制与进展患者的总生存(OS)无差异。
要点
- 脑转移患者接受ICB预后劣于无脑转移者,且脑转移灶数量多者生存更差。
- 颅外病灶疾病控制是伴或不伴脑转移患者OS的主要预测因素。
- 颅内疾病控制与颅内进展患者OS无差异,提示需关注其他终点。
核心结论
- 颅外疾病控制是伴或不伴黑色素瘤脑转移患者OS的主要预测因素。
- 脑转移患者中颅内疾病控制与进展者的OS无差异。
- 脑转移患者临床试验除颅内缓解率外应关注症状控制、生活质量或OS等终点。
研究设计与样本
- 回顾性队列研究,纳入2005至2017年两个三级中心接受ICB单药治疗的385例转移性黑色素瘤患者。
- 共识别177例接受ICB(伊匹木单抗、纳武利尤单抗、帕博利珠单抗)的脑转移患者。
- 有与无脑转移患者接受相似的ICB方案。
主要发现
- 脑转移患者预后较差;多于1个脑转移者生存更差。
- 颅外转移灶疾病控制与生存改善相关。
- 颅内疾病控制与颅内进展患者相比OS无差异。
临床怎么用
- 对黑色素瘤脑转移患者,应重视颅外病灶的疾病控制。
- 评估ICB疗效时,颅内疾病控制不能直接等同于OS获益。
- 临床试验设计可纳入症状控制、生活质量或OS等终点。
局限性
- 回顾性研究设计。
- 数据来自两个三级中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immune-checkpoint blockers (ICBs) significantly prolong overall survival (OS) in patients with advanced melanoma. Limited data are available on the efficacy and clinical benefit in patients with melanoma brain metastases (MBMs). The aim of this study was to determine whether ICB is active in an unselected cohort treated of patients with known brain metastases and if disease control correlates with the survival. METHODS: A total of 385 patients with metastatic malignant melanoma treated with ICB as monotherapy between 2005 and 2017 in two tertiary referral centres were included. Patient records were searched for the development of brain metastases. Demographic and clinical data of all patients were collected retrospectively. RESULTS: We identified 177 patients with MBM who received ICBs (ipilimumab, nivolumab, pembrolizumab). Patients with and without brain metastases received similar ICB regimens. Prognosis was inferior in patients with brain metastases; patients with >1 brain metastasis showed even poorer survival. For extracranial (ec) metastases, disease control was associated with improved survival. However, when comparing patients with intracranial (ic) disease control during immunotherapy to patients with ic disease progression, no difference in OS could be observed. CONCLUSIONS: In our study, ec disease control was the dominant predictive factor for OS in both patients with or without melanoma brain metastases. These data indicate that clinical trials in melanoma patients with brain metastases should address end-points such as symptom control, quality of life or OS in addition to ic response rates.
引用
- Milsch L, Gesierich A, Kreft S, et al. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. Eur J Cancer. 2018. PMID: 29906735. doi:10.1016/j.ejca.2018.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。